

To
the Honourable

Mrs Z. Dede, President of Pricing Committee

Mr. N. karapanos, Director of the Directorate for Medicines & Pharmacies

Κοιν. : Prof. I. Tountas, President of EOF
Mrs M. Skouroliakou, 1st Vice-President

Athens, 16 November 2012

Subject: Orphan Medicines

Dear Mrs Dede,
Dear Mr. Karapanos

Taking into consideration the minutes of the Pricing Committee 16.10.2012 re Orphan Medicines, we would like to ask for the review of the prices of Orphan Medicines, according to your decision, as described in the minutes of the Committee.

Since the impact of Orphan Medicines in total pharmaceutical expenditure is low, as it does not exceed the € 100 million (2, 5% of total pharmaceutical expenditure), we would like to point out the seriousness of our request, so that the aforementioned medicines are not withdrawn and patients will continue to have access to unique and valuable treatments for their life.

Thank you for the proper attention in our statement.

Sincerely yours,



Ioannis Vlontzos
Vice - President



Christos Dakas
Co-ordinator of SFEE Committee for Orphan Medicines



Nikos Kefalas
Vice-President